Full Press Release Details
Immutep Receives Australian R&D Tax Incentive.
IMMP
Immutep Receives Australian R&D Tax Incentive
Key Takeaway: Immutep Receives Australian R&D Tax Incentive
Price reaction · baseline $2.29 (2022-11-11 close) · 4 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-3.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)